An amendment to an international Phase 3 clinical trial for prostate cancer drug Xtandi (enzalutamide) will cut the sample size by 120 subjects and provide results later this year, nearly two years ahead of schedule.
Xtandi was created by Pfizer Inc. along with the U.S. subsidiary of Tokyo-based Astellas Pharma Inc. XXtandi has already been proven effective in metastatic forms of castration-resistant prostate cancer, according to a June 9 press release from the manufacturers. The new test will assess its results with non-metastatic forms of the disease.
Astellas Senior Vice President Steven Benner said altering the study may help fight the disease more quickly after diagnosis.
“We are continually looking to evaluate this medicine for men facing earlier stage disease,” Benner said in the release. “By amending the protocol for PROSPER (the clinical trial), we hope to be able to accelerate the evaluation of the data in this area of medical need.”
XTANDI is an orally administered androgen blocker thought to disrupt the effects of the hormone on tumor growth, the announcement said.
